Purpose: To increase psychiatric providers' adherence to the recommendations set forth in the American Psychiatric Association Consensus Guideline for metabolic management of patients prescribed second generation antipsychotic medications (SGAs).
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Background
Antipsychotic medications are an integral component of treatment for many psychiatric disorders and psychiatric symptoms. Given that treatment for many common psychiatric disorders often requires lifelong psychotropic management and that as a profession, psychiatry often prescribes antipsychotics for off label uses; the demand for antipsychotic medication has significantly increased over the past generation. 1, 3, 4, 6 Typically prescribed for psychosis, first generation antipsychotics (FGAs) were developed in the 1950's and often referred to as "neuroleptics" because of their capacity to affect psychomotor slowing, emotional quieting and affective indifference.
Regrettably, FGAs also have a higher risk of neurological side effects including tardive dyskinesia and extrapyramidal dystonia. 1 Second generation antipsychotics (SGAs) came onto the market in the 1980's.
Also called "atypical", these newer SGAs demonstrated a lower risk of neurological side effects, but in time, were linked with a proven risk of developing metabolic side effects including weight gain with an increase in waist circumference, hyperglycemia, dyslipidemia subsequently leading to cardiovascular disease and/or diabetes. 1, 3, 4, 6 Recognizing the severe chronicity of the consequences of the metabolic side Table 1 Metabolic Monitoring Protocol During the course of treatment with SGAs, clinicians who prescribe the SGAs should be monitoring weight through the entire term of treatment. Additionally, the baseline and periodic monitoring of blood pressure, waist circumference, and laboratory values should be routinely assessed. 1, 8 The reasons why SGAs cause metabolic changes is not fully understood. The six SGAs, noted in Table 2 , differ in chemical makeup and efficacy and some contribute to metabolic changes more than others. The SGA medications are not created equal nor are they prescribed interchangeably for psychiatric conditions and symptomology. The risk versus benefit to the patient who is prescribed a particular SGA and the "return on investment" in alleviating symptoms needs to be taken into consideration even while monitoring for metabolic shifts. For some, the efficacy of management of the psychiatric symptoms, regardless of the metabolic risks or changes, outweighs any consideration to switch to an alternate medication. 
Practice Change
The psychiatrist residents as providers at the psychiatric behavioral health clinic were observed to rarely be obtaining a baseline blood pressure on adult patients. The clinic had made available stethoscopes and two manual blood pressure cuffs occasionally used by the psychiatric providers for obtaining a blood pressure reading. The newly adopted EHR did have provision in the psychiatric visit documentation template for the baseline biometrics, yet, because the clinic did not have a scale during the retrospective data period, height, weight, or body mass index were not being documented at the time of the psychiatric visit.
Despite the acceptance and acknowledgement of the importance of the guideline, psychiatric clinics as a whole do not appear to be routinely following the ADA/APA/ACE/NAASO guideline. 6, 11 Psychiatrists are often reluctant to collect and document blood pressure, height and weight, and are particularly averse to measuring waist circumference. Provider reluctance appears to be a significant impediment to the overall broad implementation of this clinical guideline. 
Outcomes
Utilizing data from the EHR, the project results were intended to be evaluated on three objectives: a 20% increase in the documentation rate of blood pressure, a 20% increase over baseline in the documentation rate of body mass index, and a 20 % increase over baseline in the documentation of waist circumference.
The control chart in Table 3 below compares pre-intervention data with the results of the post intervention data in the blood pressure monitoring rate. The blue dots reveal that 5.31% of the time during the retrospective data collection period a blood pressure was taken and documented at the time of the psychiatric visit. In other words, a blood pressure was occasionally taken and documented during this time. The red dots falling below the mean flag an undesirable trend noting essentially 0% of the time was blood pressure was taken and documented at the time of the psychiatric visit. Following the educational intervention to the providers, an upward trajectory is noted during the month of post intervention data collection. The 70% documentation rate of blood pressure is well above the target outcome of a 20% increase over baseline. Table 3 of the post intervention data for BP and BMI. During the retrospective data collection time period it was business as usual as evidenced by the blue dots. Falling below the mean, an undesirable trend is noted by the red dots during the retrospective data collection period depicting a 0% baseline documentation rate of blood pressure and/or BMI. Following the educational intervention to the providers, a 58.23% increase over baseline is noted well above the target outcome of a 20%.increase. Table 4 For the purposes of this pilot study, difficulty in ordering the disposable tape measures, provider reluctance, and provider time constraints influenced cost and value in continuing to pursue documentation of waist circumference in the electronic health record at this time. The stakeholders agreed that this data point was not feasible for the pilot study. Therefore, for this pilot study, the standard of care in regards to the ADA/APA/ACE/NAASO guideline was partially met.
Implications for practice
The project heralded several unintended, yet significantly positive outcomes.
Once it was established that blood pressure and BMI monitoring were to become a routine part of the psychiatric visit, a process protocol was developed in collaboration with the primary care and family medicine medical directors to identify and manage 
